{"id":390831,"date":"2017-11-29T00:00:00","date_gmt":"2017-11-29T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unnecv0003-2017-biopharma-heart-failure-unmet-need-acute-heart-failure-us-eu-2017\/"},"modified":"2026-04-18T11:40:33","modified_gmt":"2026-04-18T11:40:33","slug":"unnecv0003-2017-biopharma-heart-failure-unmet-need-acute-heart-failure-us-eu-2017","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unnecv0003-2017-biopharma-heart-failure-unmet-need-acute-heart-failure-us-eu-2017\/","title":{"rendered":"Heart Failure | Unmet Need | Acute Heart Failure | US\/EU | 2017"},"content":{"rendered":"<p>The standard of care in <abbr title=\"acute heart failure\">AHF<\/abbr> has remained largely unchanged since the 1970s, resulting in a highly genericized market. <abbr title=\"acute heart failure\">AHF<\/abbr> patients continue to experience high rates of mortality and morbidity because no therapy to date has been able to improve hard clinical outcomes. In this report, we discuss how current therapies are differentiated based on their performance on key drug attributes and measure the impact of these attributes on cardiologists\u2019 prescribing behavior. We also discuss the most important unmet needs in the treatment of <abbr title=\"acute heart failure\">AHF<\/abbr>; according to physicians surveyed, the most important unmet need is reducing <abbr title=\"acute heart failure\">AHF<\/abbr> patients\u2019 mortality rate. Understanding the importance of these unmet needs helps identify the most attractive opportunities in <abbr title=\"acute heart failure\">AHF<\/abbr> treatment. We then consider which emerging therapies, if any, can capitalize on these opportunities. Our conjoint analysis reveals the trade-offs in key attributes, such as rate of mortality, rehospitalization, and price, that surveyed physicians are willing to make when considering new treatment options for <abbr title=\"acute heart failure\">AHF<\/abbr>.<\/p>\n<p><strong>Questions Answered:<\/strong><\/p>\n<ul>\n<li>What are the treatment drivers and goals for <abbr title=\"acute heart failure\">AHF<\/abbr>?<\/li>\n<li>Which attributes are the most influential, which have limited impact, and which are hidden opportunities?<\/li>\n<li>How do current therapies perform on key treatment drivers and goals for <abbr title=\"acute heart failure\">AHF<\/abbr>?<\/li>\n<li>What are the prevailing areas of unmet need and opportunity in <abbr title=\"acute heart failure\">AHF<\/abbr>?<\/li>\n<li>What trade-offs across different clinical attributes and price are acceptable to <abbr title=\"United States\">U.S.<\/abbr> and European cardiologists for a hypothetical new <abbr title=\"acute heart failure\">AHF<\/abbr> drug?<\/li>\n<\/ul>\n<p><strong>Markets covered:<\/strong> United States, France, Germany, United Kingdom.<\/p>\n<p><strong>Primary research: <\/strong>Survey of 60 <abbr title=\"United States\">U.S.<\/abbr> and 30 European cardiologists fielded in January 2017.<\/p>\n<p><strong>Key companies:<\/strong><abbr title=\"Bristol-Myers Squibb\">Bristol-Myers S<\/abbr>quibb, Cardiorentis, Janssen, Novartis<\/p>\n<p><strong>Key drugs:<\/strong> inotropic sympathomimetics, loop diuretics, Natrecor, nitrate vasodilators, <abbr title=\"phosphodiesterase 3\">PDE3<\/abbr> inhibitors, serelaxin<\/p>\n","protected":false},"template":"","class_list":["post-390831","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-acute-heart-failure","biopharma-therapy-areas-heart-failure","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-890"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390831","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390831\/revisions"}],"predecessor-version":[{"id":393955,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390831\/revisions\/393955"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390831"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}